These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36111007)

  • 41. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
    Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
    Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Construction and validation of an m6A RNA methylation regulator prognostic model for early-stage clear cell renal cell carcinoma.
    Wang Z; Zhang M; Seery S; Zheng G; Wang W; Zhao Y; Wang X; Zhang Y
    Oncol Lett; 2022 Aug; 24(2):250. PubMed ID: 35761938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of ligamentum flavum hypertrophy based on m6A RNA methylation modification and the immune microenvironment.
    He Z; Zhu Z; Tang T; Guo P; Gao M; Li B; Nguyen TCT; Chen H; Liu X; Zhou Z; Liu S
    Am J Transl Res; 2022; 14(12):8800-8827. PubMed ID: 36628248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. m6A RNA methylation regulator-related signatures exhibit good prognosis prediction ability for head and neck squamous cell carcinoma.
    Zhai Y; Zheng L
    Sci Rep; 2022 Sep; 12(1):16358. PubMed ID: 36175504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma.
    Fang J; Hu M; Sun Y; Zhou S; Li H
    DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33085515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
    Yu ZL; Zhu ZM
    Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
    Front Oncol; 2022; 12():774307. PubMed ID: 35141159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The hub ten gene-based risk score system using RNA m
    Yuan B; Liu W; Huo M; Zhang J; Yang Y; Gao T; Yin X; Yang T; Teng X; Huang W; Yu H
    Breast Cancer; 2022 Jul; 29(4):645-658. PubMed ID: 35174450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
    Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
    Front Genet; 2021; 12():790888. PubMed ID: 34976022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
    Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
    Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
    Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
    Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
    Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
    Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma.
    Wang Y; Li N; Tian D; Zhou CW; Wang YH; Yang C; Zeng MS
    Cancer Manag Res; 2021; 13():6451-6471. PubMed ID: 34429653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.
    Wang Y; Sun N; He R; Wang Z; Jin J; Gao T; Qu J
    Clin Exp Med; 2024 May; 24(1):92. PubMed ID: 38693353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. m6A-related lncRNAs predict prognosis and indicate immune microenvironment in acute myeloid leukemia.
    Zhong F; Yao F; Cheng Y; Liu J; Zhang N; Li S; Li M; Huang B; Wang X
    Sci Rep; 2022 Feb; 12(1):1759. PubMed ID: 35110624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
    Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
    Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
    [No Abstract]   [Full Text] [Related]  

  • 57. Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapy.
    Wan P; Zhong L; Yu L; Shen C; Shao X; Chen S; Zhou Z; Wang M; Zhang H; Liu B
    Front Immunol; 2024; 15():1384633. PubMed ID: 38799454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer.
    Yu L; Wang L; Sun J; Zhou X; Hu Y; Hu L; He Y; Lin C; Chen J; Xu X; Dunlop MG; Theodoratou E; Ding K; Li X
    Front Genet; 2023; 14():885930. PubMed ID: 36936424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.
    Yu Z; He Q; Xu G
    Transl Cancer Res; 2022 Dec; 11(12):4303-4314. PubMed ID: 36644186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
    Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
    Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.